Meeting
2011 ASCO Annual Meeting
A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
Authors
E. Angevin
Institut Gustave Roussy, Villejuif, France
E. Angevin , V. Grünwald , A. Ravaud , D. E. Castellano , C. C. Lin , J. E. Gschwend , A. L. Harzstark , J. Chang , Y. Wang , M. M. Shi , B. J. Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT00715182
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4551)
Abstract #
4551
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
First Author: Thomas E. Hutson
Poster
2015 ASCO Annual Meeting
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
First Author: Thomas Hutson
Poster
2023 ASCO Annual Meeting
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.
First Author: Honghai Dai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study.
First Author: Do-Youn Oh